Kensei Tobinai

Summary

Affiliation: National Cancer Center
Country: Japan

Publications

  1. ncbi request reprint Two entities of precursor T-cell lymphoblastic leukemia/lymphoma based on radiologic and immunophenotypic findings
    Yasushi Onishi
    Hematology Division, National Cancer Center Hospital, Tsukiji, Chou ku, Tokyo, Japan
    Int J Hematol 80:43-51. 2004
  2. ncbi request reprint Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan
    Sung Won Kim
    Hematology and Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
    Blood 108:382-9. 2006
  3. ncbi request reprint Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation
    Yasushi Onishi
    Division of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
    Int J Hematol 85:256-63. 2007
  4. pmc Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas
    Kensei Tobinai
    Department of Hematology, and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tsukiji, Chuo Ku, Tokyo, Japan
    Curr Hematol Malig Rep 7:235-40. 2012
  5. doi request reprint Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
    Kensei Tobinai
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Int J Hematol 92:563-70. 2010
  6. ncbi request reprint Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma
    Kensei Tobinai
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
    J Clin Oncol 24:174-80. 2006
  7. doi request reprint Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
    Kensei Tobinai
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, and School of Medicine, Keio University, Tokyo, 104 0045, Japan
    Cancer Sci 100:158-64. 2009
  8. ncbi request reprint Clinical trials for malignant lymphoma in Japan
    Kensei Tobinai
    Hematology Division, National Cancer Center Hospital, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 34:369-78. 2004
  9. doi request reprint Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results
    Kensei Tobinai
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tsukiji, Chuo Ku, Tokyo, Japan
    Cancer Sci 101:2579-85. 2010
  10. ncbi request reprint Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma
    K Tobinai
    Hematology and Clinical Laboratory Divisions, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Ann Oncol 15:821-30. 2004

Collaborators

Detail Information

Publications133 found, 100 shown here

  1. ncbi request reprint Two entities of precursor T-cell lymphoblastic leukemia/lymphoma based on radiologic and immunophenotypic findings
    Yasushi Onishi
    Hematology Division, National Cancer Center Hospital, Tsukiji, Chou ku, Tokyo, Japan
    Int J Hematol 80:43-51. 2004
    ..This study was performed in a single institution, was retrospective, and had a limited number of patients; multicenter confirmatory studies are warranted...
  2. ncbi request reprint Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan
    Sung Won Kim
    Hematology and Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
    Blood 108:382-9. 2006
    ..Although myeloablative allo-HSCT represents an effective therapeutic option for patients with NHL, more work is still needed to decrease TRM and relapse...
  3. ncbi request reprint Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation
    Yasushi Onishi
    Division of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
    Int J Hematol 85:256-63. 2007
    ..These results suggest that this regimen reduces the risk of graft failure, but further studies are needed to ameliorate transplantation-related toxicities, primarily GVHD and/or pulmonary complications...
  4. pmc Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas
    Kensei Tobinai
    Department of Hematology, and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tsukiji, Chuo Ku, Tokyo, Japan
    Curr Hematol Malig Rep 7:235-40. 2012
    ..Further preclinical and clinical investigations are needed to examine whether concomitant use of this novel agent with other agents with different mechanisms of action would be more effective for ATL and other PTCLs...
  5. doi request reprint Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
    Kensei Tobinai
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Int J Hematol 92:563-70. 2010
    ..The pharmacokinetic profiles were not different from those in non-Japanese patients. Everolimus was well tolerated at doses up to 10 mg/day and showed potential efficacy in relapsed or refractory NHL, warranting further investigation...
  6. ncbi request reprint Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma
    Kensei Tobinai
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
    J Clin Oncol 24:174-80. 2006
    ..To assess the efficacy and toxicity of oral fludarabine phosphate in patients with indolent B-NHL, we conducted a multicenter phase II study...
  7. doi request reprint Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
    Kensei Tobinai
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, and School of Medicine, Keio University, Tokyo, 104 0045, Japan
    Cancer Sci 100:158-64. 2009
    ..ClinicalTrials.gov number NCT00220285)...
  8. ncbi request reprint Clinical trials for malignant lymphoma in Japan
    Kensei Tobinai
    Hematology Division, National Cancer Center Hospital, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 34:369-78. 2004
    ..The multicenter trials by the JCOG-LSG and industry-supported new agent studies will contribute to further improvement in the treatment of malignant lymphoma...
  9. doi request reprint Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results
    Kensei Tobinai
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tsukiji, Chuo Ku, Tokyo, Japan
    Cancer Sci 101:2579-85. 2010
    ....
  10. ncbi request reprint Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma
    K Tobinai
    Hematology and Clinical Laboratory Divisions, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Ann Oncol 15:821-30. 2004
    ..To evaluate the efficacy and feasibility of rituximab monotherapy in Japanese patients with relapsed or refractory aggressive B-cell lymphoma...
  11. doi request reprint Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab
    Kensei Tobinai
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo 104 0045, Japan
    Cancer Sci 100:1344-50. 2009
    ....
  12. ncbi request reprint Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma
    Kensei Tobinai
    Hematology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Int J Clin Oncol 8:212-23. 2003
    ..Monoclonal antibodies will have significant roles in the treatment of lymphoid malignancies in the future...
  13. ncbi request reprint Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma
    Kensei Tobinai
    Hematology Division, National Cancer Center Hospital, Tokyo, Japan
    Int J Hematol 77:512-7. 2003
    ..In conclusion, cladribine is not worthy of further investigation for the treatment of ATL...
  14. ncbi request reprint Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan
    Kensei Tobinai
    Hematology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, 104 0045, Tokyo, Japan
    Cancer Chemother Pharmacol 52:S90-6. 2003
    ..It is concluded that monoclonal antibodies will have play a significant role in the treatment of hematologic malignancies in the future...
  15. ncbi request reprint Current management of adult T-cell leukemia/lymphoma
    Kensei Tobinai
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
    Oncology (Williston Park) 23:1250-6. 2009
    ..For relapsed or refractory patients, enrollment in a new-agent trial should be considered in addition to stem cell transplantation...
  16. ncbi request reprint Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan
    Kensei Tobinai
    Hematology Division, National Cancer Center Hospital, Tokyo, Japan
    Int J Hematol 76:411-9. 2002
    ..1 months. In conclusion, rituximab is a highly effective agent in relapsed indolent and aggressive B-NHL and MCL and has acceptable toxicities...
  17. doi request reprint Third annual forum on T-cell lymphoma
    Kensei Tobinai
    Department of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Expert Rev Anticancer Ther 11:693-5. 2011
    ..Submitted abstracts and poster presentations rounded off each of the sessions...
  18. doi request reprint Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study
    Kensei Tobinai
    Department of Hematology, and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
    Cancer Sci 102:1698-705. 2011
    ..University Hospital Medical Information Network no. UMIN000002974.)..
  19. ncbi request reprint Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004
    Kensei Tobinai
    National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Sci 98:1350-7. 2007
    ..In conclusion, G-CSF-supported, intensive post-remission Cx and subsequent SCT are worthy of further investigation for the treatment of adult ALL and LBL...
  20. ncbi request reprint 4. Antibody therapy for malignant lymphoma
    Kensei Tobinai
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo
    Intern Med 46:99-100. 2007
    ....
  21. doi request reprint Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan
    Kensei Tobinai
    National Cancer Center Hospital, Tokyo, Japan
    Semin Hematol 47:S5-7. 2010
    ..Clinical trials with pralatrexate, a folate analog, and denileukin diftitox, an immunoconjugate, are under discussion for patients with ATL and peripheral T-cell lymphoma (PTCL)...
  22. ncbi request reprint Proteasome inhibitor, bortezomib, for myeloma and lymphoma
    Kensei Tobinai
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Int J Clin Oncol 12:318-26. 2007
    ....
  23. doi request reprint Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
    Kensei Tobinai
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
    Cancer Sci 100:1951-6. 2009
    ..In conclusion, oral fludarabine in combination with rituximab is a highly effective and convenient therapy for patients with relapsed indolent B-NHL who have mostly been pretreated with rituximab...
  24. ncbi request reprint Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan
    K Tobinai
    Hematology Division, National Cancer Center Hospital, Tokyo, Japan
    Cancer Chemother Pharmacol 48:S85-90. 2001
    ..006 and P=0.0001, respectively). In conclusion, rituximab is more effective in indolent B-NHL than in MCL. Several prognostic factors and serum rituximab concentrations are useful for predicting the therapeutic efficacy...
  25. ncbi request reprint Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies
    Shin Mineishi
    Haematopoietic Stem Cell Transplant Unit, National Cancer Centre Hospital, Tokyo, Japan
    Br J Haematol 121:296-303. 2003
    ..Although GVHD is a major threat in RIST, appropriate induction of GVHD may be associated with anti-tumour activity in RIST comparable to that of CST...
  26. ncbi request reprint Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen
    Dai Maruyama
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
    Biol Blood Marrow Transplant 13:932-41. 2007
    ..In conclusion, these results suggest that the antileukemia/lymphoma effect associated with RIST is comparable to that associated with CST. RIST appears to be feasible for the treatment of hematologic malignancies not in remission...
  27. ncbi request reprint Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study
    Dai Maruyama
    Hematology and Stem Cell Transplantation Division, Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 37:216-23. 2007
    ..The incidence of primary bone lymphoma (PBL) is so rare that many of its aspects remain unknown. A number of studies have been reported from Western countries, but only a few reports are available from Asia...
  28. doi request reprint Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with
    Dai Maruyama
    Hematology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Int J Hematol 92:732-43. 2010
    ..In conclusion, our modified CODOX-M/IVAC regimen is well tolerated and highly effective in Japanese adult patients with BL and intermediate DLBCL/BL, warranting a larger study for confirmation...
  29. doi request reprint Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation
    Shigeo Fuji
    Department of Hematology and Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
    Biol Blood Marrow Transplant 14:510-7. 2008
    ..02). The present findings suggest that the CRP value may reflect the net degree of tissue damage because of the conditioning regimen, infection, and allogeneic immune reactions, all of which lead to subsequent aGVHD and NRM...
  30. doi request reprint Phase II study of intensive post-remission chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia and lymphoblastic lymphoma: Japan Clinical Oncology Group Study, JCOG9402
    Teruhisa Azuma
    National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 42:394-404. 2012
    ..To evaluate the efficacy and safety of intensive post-remission chemotherapy for untreated patients aged 15-69 years with adult acute lymphoblastic leukemia and lymphoblastic lymphoma in a multicenter Phase II study...
  31. doi request reprint Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial
    Takashi Watanabe
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
    J Clin Oncol 29:3990-8. 2011
    ..To improve progression-free survival (PFS) in patients treated with R-CHOP as the primary end point, we conducted a phase III study...
  32. doi request reprint Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution
    Suguru Fukuhara
    Department of Hematology, and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, Japan
    Eur J Haematol 87:434-40. 2011
    ..Primary breast lymphoma (PBL) is rare, and its clinical behavior and standard initial treatment are not yet established...
  33. doi request reprint Diagnosis and evaluation of intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation following reduced-intensity and myeloablative conditioning regimens
    Satoshi Yamasaki
    Division of Hematology Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Int J Hematol 97:421-6. 2013
    ..These differences in the RIC and MAC groups suggest that regimen-specific therapeutic strategies are required for diagnosing intestinal GVHD...
  34. ncbi request reprint Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma
    Takashi Watanabe
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, 5 1 1, Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Cancer Sci 96:903-10. 2005
    ..4 mCi/kg (14.8 MBq/kg). This dose of radioimmunotherapy was feasible when patients with altered biodistribution of In2B8 were excluded, and it was highly effective. (Cancer Sci 2005; 96: 903-910)...
  35. doi request reprint Carcinoma of donor origin after allogeneic peripheral blood stem cell transplantation
    Wataru Munakata
    Departments of Hematology and Hematopoietic Stem Cell Transplantation, Division of Thoracic Surgery, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Am J Surg Pathol 36:1376-84. 2012
    ..Our observations suggest that transfused peripheral blood cells may be involved in the development of cancers after allogeneic peripheral blood stem cell transplantation...
  36. doi request reprint Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy
    Akiko Miyagi Maeshima
    Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan
    Cancer Sci 100:54-61. 2009
    ..In conclusion, B-NHL showed various histological and immunophenotypic changes after rituximab therapy, including not only CD20 loss but also proliferation of plasmacytoid cells or transformation to special subtypes of lymphoma...
  37. doi request reprint Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy
    Akiko Miyagi Maeshima
    Department of Pathology and Clinical Laboratory, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, 104 0045 Tokyo, Japan Electronic address
    Hum Pathol 44:2529-35. 2013
    ..Bcl-2 expression and marginal zone differentiation were not prognostic indicators in follicular lymphoma patients treated with rituximab-containing therapy. ..
  38. ncbi request reprint Primary mediastinal large B-cell lymphoma: a single-institution clinical study in Japan
    Naohiro Sekiguchi
    Hematology Division, National Cancer Center Hospital, Tokyo, Japan
    Int J Hematol 79:465-71. 2004
    ..Because this investigation was a single-institution study with a limited number of patients, however, multicenter confirmatory studies are needed...
  39. doi request reprint Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy
    Akiko M Maeshima
    Department of Pathology and Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan
    Am J Surg Pathol 37:563-70. 2013
    ..As the changes in morphology and CD20 expression after rituximab therapy vary widely, careful follow-up and rebiopsy are recommended...
  40. doi request reprint Lymphoma study group of JCOG
    Kunihiro Tsukasaki
    Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Science, Sakamoto, Nagasaki, Japan
    Jpn J Clin Oncol 42:85-95. 2012
    ..The multicenter trials by the JCOG-LSG combining new modalities such as molecular-targeting agents will contribute to further improvements in the treatment of lymphoid malignancies...
  41. doi request reprint Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature
    Hiroki Yokoyama
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
    Int J Hematol 88:443-7. 2008
    ....
  42. ncbi request reprint Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients
    Mutsuko Ohnishi
    Stem Cell Transplant Unit, and Hematology Division, National Cancer Center Hospital, Tokyo 104 0045, Japan
    Transplantation 73:812-5. 2002
    ..Recipients of allogeneic hematopoietic stem cell transplantation (HSCT) carry the highest risk of fatal HBV disease (up to 12%)...
  43. doi request reprint Follicular lymphoma of the duodenum: a clinicopathologic analysis of 26 cases
    Kazuhiro Sentani
    Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 38:547-52. 2008
    ..Follicular lymphomas (FLs) occur commonly in the lymph nodes, and duodenal FL (DFL) is reported to be rare...
  44. ncbi request reprint A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma
    Kunihiko Takeyama
    Hematology Division, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 33:78-85. 2003
    ..However, the optimal dose of granulocyte colony-stimulating factor (G-CSF) for PBSC mobilization in combination with chemotherapy for autograft remains unknown...
  45. doi request reprint Nocardia exalbida brain abscess in a patient with follicular lymphoma
    Makiko Ono
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
    Int J Hematol 88:95-100. 2008
    ..It should be noted that such an infection can occur in patients treated with conventional chemotherapy against malignant lymphoma...
  46. ncbi request reprint A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002
    Tomohiro Kinoshita
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Int J Hematol 80:341-50. 2004
    ..An increase in the DI of doxorubicin in multidrug combination chemotherapy did not improve the survival of patients with intermediate- or high-grade NHL...
  47. ncbi request reprint Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients
    Kazuki Tanimoto
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital and Research Institute, Tokyo, Japan
    Jpn J Clin Oncol 37:337-44. 2007
    ....
  48. doi request reprint Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma
    Dai Maruyama
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
    Int J Hematol 88:396-402. 2008
    ..Although this investigation was a preliminary study with a small number of patients, our results suggested that pro-inflammatory cytokines causing bortezomib-associated fever were secreted from BMSCs rather than MM cells...
  49. ncbi request reprint [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody]
    Kensei Tobinai
    Hematology Division, National Cancer Center Hospital
    Nihon Rinsho 60:468-72. 2002
    ..The overall response rates in relapsed indolent B-cell lymphoma and mantle cell lymphoma were 61%(37/61) and 46%(6/13), respectively. Rituximab is a novel, effective anti-lymphoma agent with acceptable toxicities...
  50. ncbi request reprint Successful treatment of a primary gastric T-cell lymphoma lacking the human T-cell leukemia virus type 1
    Shinichi Yachida
    Gastric Surgery Division, National Cancer Center Hospital, Tokyo, Japan
    Hepatogastroenterology 57:383-7. 2010
    ..We conclude that primary gastric T-cell lymphomas without HTLV-1 should be managed in the same way as the more common diffuse large B-cell type gastric lymphomas...
  51. doi request reprint Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia: a single-center analysis of 47 patients
    Hiroki Yokoyama
    Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
    Int J Hematol 92:334-41. 2010
    ..The present findings warrant future prospective studies...
  52. ncbi request reprint Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation
    Shigeo Fuji
    Department of Hematology and Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
    Transplantation 84:814-20. 2007
    ..Van den Berghe et al. showed that the strict glucose control improved the outcome of patients treated in the intensive care unit, and this point was evaluated in this study in a HSCT setting...
  53. ncbi request reprint Impact of stem cell source and conditioning regimen on erythrocyte recovery kinetics after allogeneic haematopoietic stem cell transplantation from an ABO-incompatible donor
    Yoshinobu Kanda
    Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan
    Br J Haematol 118:128-31. 2002
    ..The use of a reduced-intensity regimen combining a purine analogue and busulphan did not delay erythrocyte recovery after major ABO-incompatible transplantation, suggesting this regimen had a strong activity against host plasma cell...
  54. ncbi request reprint Diffuse large B-cell lymphoma with extra Bcl-2 gene signals detected by FISH analysis is associated with a "non-germinal center phenotype"
    Shigeru Kusumoto
    Hematology Division, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Am J Surg Pathol 29:1067-73. 2005
    ..The DLBCLs with Bcl-2 protein overexpression were classified into at least two heterogeneous molecular groups, based on the results of the FISH analysis...
  55. doi request reprint Bcl-2, Bcl-6, and the International Prognostic Index are prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy
    Akiko Miyagi Maeshima
    Department of Pathology and Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan
    Cancer Sci 103:1898-904. 2012
    ..In conclusion, Bcl-2 positivity, Bcl-6 negativity, and higher IPI were indicators of shorter PFS and OS plus primary refractory disease in patients with DLBCL in the rituximab era...
  56. doi request reprint Diffuse large B-cell lymphoma after transformation from low-grade follicular lymphoma: morphological, immunohistochemical, and FISH analyses
    Akiko Miyagi Maeshima
    Clinical Laboratory, National Cancer Center Hospital, Tsukiji 5 1 1, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Sci 99:1760-8. 2008
    ..BCL6 translocation was detected in 1/6 (17%) DLBCLs without IGH/BCL2 fusion. Thus, although the morphological features and FISH results for DLBCL were consistent with transformed FL, the immunophenotype showed wide heterogeneity...
  57. ncbi request reprint The application of molecular analyses for primary granulocytic sarcoma with a specific chromosomal translocation
    Naohiro Sekiguchi
    Hematology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, Japan
    Int J Hematol 82:210-4. 2005
    ....
  58. ncbi request reprint Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma
    Takeshi Saito
    Hematopoietic Stem Cell Transplantation and Hematology Division, National Cancer Center Hospital, Tokyo 104 0045, Japan
    Clin Cancer Res 8:1014-20. 2002
    ..We therefore performed a pilot study to evaluate the feasibility of a novel 2-CdA-based reduced-intensity stem cell transplantation (RIST) regimen...
  59. ncbi request reprint T-cell large granular lymphocyte leukemia of donor origin after cord blood transplantation
    Shigeru Kusumoto
    Division of Hematology and Stem Cell Transplantation, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Clin Lymphoma Myeloma 7:475-9. 2007
    ....
  60. ncbi request reprint EBV-positive Burkitt lymphoma as a late-onset posttransplantion lymphoproliferative disorder after allogeneic stem cell transplantation
    Naohiro Sekiguchi
    Hematology Division, National Cancer Center Hospital, Tokyo, Japan
    Int J Hematol 79:387-9. 2004
    ..The patient achieved complete response with intensive chemotherapy. To our knowledge, this is the first report of Burkitt lymphoma as a PTLD occurring after allogeneic SCT...
  61. ncbi request reprint T(11;18)-bearing pulmonary mucosa-associated lymphoid tissue lymphoma responding to cladribine
    Shigeru Kusumoto
    Hematology Division, National Cancer Center Hospital, Tsukiji, Chou ku, Tokyo, Japan
    Int J Hematol 80:70-4. 2004
    ..These findings show the unique clinical features of this particular indolent B-cell lymphoma with t(11;18) translocation and suggest the potential therapeutic usefulness of glucocorticoid and cladribine...
  62. pmc Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma
    Junko Nomoto
    Hematology Division, National Cancer Center Hospital, Tokyo, Japan
    BMC Cancer 12:457. 2012
    ..However, the detection of this in primary Hodgkin lymphoma (HL) specimens is hampered by the scarcity of Hodgkin Reed-Sternberg (HR-S) cells even after enrichment by micro-dissection...
  63. doi request reprint Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma
    Kohei Tada
    Department of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
    Am J Hematol 87:770-5. 2012
    ..These results suggest that allo-HCT may be a promising option for patients with not only advanced FL but also DLBCL associated with FL...
  64. pmc Fluorescence in situ hybridization (FISH) analysis of primary ocular adnexal MALT lymphoma
    Kazuki Tanimoto
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, Japan
    BMC Cancer 6:249. 2006
    ....
  65. ncbi request reprint Primary mediastinal lymphoma: characteristic features of the various histological subtypes on CT
    Ukihide Tateishi
    Division of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan
    J Comput Assist Tomogr 28:782-9. 2004
    ....
  66. ncbi request reprint Enteropathy-type T-cell lymphoma showing repeated small bowel rupture and refractoriness to chemotherapy: a case report
    Itaru Kataoka
    Hematology Division, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 32:546-9. 2002
    ..Particular attention should be paid to the peculiar clinical manifestations of enteropathy-type T-cell lymphoma such as malnutrition, frequent intestinal perforation and refractoriness to chemotherapy...
  67. ncbi request reprint Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation
    Yuriko Morita
    Division of Hematology and Stem Cell Transplantation, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Int J Cancer 119:1360-7. 2006
    ..A higher positive rate for WT1-specific CTL and a correlation with the clinical response suggest that WT1 may be a useful antigen for a wider monitoring application...
  68. ncbi request reprint Nutritional support for patients suffering from intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    Osamu Imataki
    Division of Hematopoietic Stem Cell Transplantation and Hematology, National Cancer Center Hospital, Tokyo, Japan
    Am J Hematol 81:747-52. 2006
    ..However, it is possible that continuing oral intake could be beneficial in many patients compared to total parenteral nutrition (TPN)...
  69. doi request reprint Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas
    Takashi Watanabe
    Hematology Division, National Cancer Center Hospital, 5 1 1, Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Leuk Lymphoma 51:813-21. 2010
    ..024) remained significant. We discuss the need to establish the importance and meaning of TP and to develop new strategies for patients with PT/NKCLs allowing for TP, especially with worse histologic subtypes...
  70. doi request reprint Follicular lymphoma with marked monocytoid or plasmacytoid differentiation and tiny or indistinct follicles: a case study of four patients
    Kenji Yamada
    Pathology Division, National Cancer Center Hospital, Tokyo, Japan
    Leuk Lymphoma 52:804-13. 2011
    ..Identifying tiny CD10+/BCL-2+ neoplastic follicles, detecting IGH/BCL2 fusion by FISH, and considering a history of FL are crucial for diagnosing such exceptional cases of FL...
  71. ncbi request reprint Follicular lymphoma subgrouping by fluorescence in situ hybridization analysis
    Naohiro Sekiguchi
    Hematology Division, National Cancer Center Hospital, Tokyo, Japan
    Cancer Sci 96:77-82. 2005
    ..Immunostaining of both Bcl-2 and CD10 was highly predictable for the presence of t(14;18); the positive predictive value was 75%, suggesting the usefulness of the staining...
  72. doi request reprint Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma
    Takashi Watanabe
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
    Cancer Sci 101:196-200. 2010
    ..0 months. The median time to achieve CRu among the three patients was 8 months. These data suggest that further investigations of vorinostat in non-Hodgkin lymphoma, focusing on FL and MCL, are warranted...
  73. ncbi request reprint [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma]
    Kensei Tobinai
    Hematology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Gan To Kagaku Ryoho 29:473-80. 2002
    ..Its minimal myelotoxicity allows rituximab to be combined with full doses of anticancer agents. Ongoing clinical trials will define the future role of rituximab in the treatment of B-cell lymphoma...
  74. doi request reprint Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study
    Yukio Kobayashi
    Hematology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Int J Hematol 89:460-9. 2009
    ..Remission lasted longer in a subset of patients than in non-Japanese patients in earlier studies. Further studies of this agent are warranted to establish standard therapy...
  75. doi request reprint Secondary CD5+ diffuse large B-cell lymphoma not associated with transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter syndrome)
    Akiko Miyagi Maeshima
    Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Am J Clin Pathol 131:339-46. 2009
    ..Groups 1 and 2 showed the gain of CD5 during the clinical course or transformation of the tumors, suggesting that CD5 expression is closely associated with the progression of B-cell lymphoma...
  76. ncbi request reprint Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study
    T Igarashi
    Hematology and Oncology Division, National Cancer Center Hospital East, Kashiwa, Tokyo, Japan
    Ann Oncol 13:928-43. 2002
    ..The aim of the study was to determine factors affecting the toxicity and efficacy of rituximab monotherapy in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma (MCL)...
  77. ncbi request reprint Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies
    T Hamaki
    Hematopoietic Stem Cell Transplant Unit, National Cancer Center Hospital, Tokyo, Japan
    Bone Marrow Transplant 33:891-900. 2004
    ..In view of the significant association between GVHD or ATG and DFS, defined management of GVHD following RIST should become a major target of clinical research...
  78. ncbi request reprint Early onset Pneumocystis carinii pneumonia after allogeneic peripheral blood stem cell transplantation
    T Saito
    Hematopoietic Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan
    Am J Hematol 67:206-9. 2001
    ..Intravenous TMP/SMX failed to improve the lesion. This is the earliest onset PCP in the literature after HSCT despite the prophylactic administration of TMP/SMX before transplant...
  79. doi request reprint Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
    Kuniaki Itoh
    Division of Oncology and Hematology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Int J Hematol 91:446-55. 2010
    ..7% in the low-risk group (no adverse factor), 87.9% in the intermediate-risk group (1 adverse factor) and 73.3% in the high-risk group (2 adverse factors). This simple prognostic model for HL warrants further validation studies...
  80. doi request reprint Adult T-cell leukemia-lymphoma: current treatment strategies and novel immunological approaches
    Ryuji Tanosaki
    Pathology and Clinical Laboratory Medicine Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, Japan
    Expert Rev Hematol 3:743-53. 2010
    ....
  81. ncbi request reprint CD56-positive small round cell tumor: osseous plasmacytoma manifested in osteolytic tumors of the iliac bone and femora
    Tsutomu Kouno
    Hematology Division, National Cancer Center Hospital 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 35:90-3. 2005
    ..Locally infiltrating osteolytic bone tumors should be examined for surface immunoglobulin light chains as well as CD56 expression when plasmacytoma is suspected...
  82. ncbi request reprint Chemotherapy: the more, the better in malignant lymphoma?
    K Tobinai
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Cancer Chemother Pharmacol 40:S110-4. 1997
    ..If promising results are obtained from these trials a randomized phase III trial will be considered to compare the best dose-intensive regimen with standard CHOP...
  83. ncbi request reprint Detection of t(I 1; 18) in MALT-type lymphoma with dual-color fluorescence in situ hybridization and reverse transcriptase-polymerase chain reaction analysis
    Y Kobayashi
    Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan
    Diagn Mol Pathol 10:207-13. 2001
    ..Direct visualization using dual-color FISH on samples serves as a molecular tool for management of MALT-type lymphoma with API2/MLT gene fusion...
  84. ncbi request reprint Analysis of myelodysplastic syndrome clones arising after multiple myeloma: a case study by correlative interphase cytogenetic analysis
    Y Kobayashi
    Department of Hematology Oncology, Institute of Medical Science, The University of Tokyo, Japan
    Jpn J Clin Oncol 29:374-7. 1999
    ..Chromosomal analysis performed after the development of MDS revealed monosomy of chromosome 9 in all the meta-phases. We wished to identify the extent of the clone with the chromosomal abnormality originating from MDS clone...
  85. ncbi request reprint Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505
    K Itoh
    Division of Hematology and Oncology, National Cancer Center Hospital East, Kashiwa, Japan
    Ann Oncol 13:1347-55. 2002
    ..The aim of the present study was to explore a suitable therapeutic-intensified regimen for the treatment of aggressive NHL...
  86. ncbi request reprint Delayed recovery of neutrophil counts after peripheral stem cell transplantation which improved with administration of a minimal dose of G-CSF: a case report
    S Mineishi
    Hematopoietic Stem Cell Transplantation Immunotherapy Unit, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 31:43-5. 2001
    ..As the response occurred on the day following G-CSF administration, a mobilization defect is suspected to be the mechanism of this delayed engraftment...
  87. ncbi request reprint Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. The lenograstim/Lymphoma Study G
    K Itoh
    Division of Hematology and Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Leuk Lymphoma 38:521-32. 2000
    ..The mobilization kinetics of circulating progenitor cells in patients with aggressive NHL is dependent on the dosage and schedule of CHOP...
  88. ncbi request reprint Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide
    T Ohtsu
    Department of Medicine, National Cancer Center Hospital East, Chiba, Japan
    Jpn J Clin Oncol 28:502-6. 1998
    ....
  89. ncbi request reprint Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group
    K Tobinai
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo
    Ann Oncol 9:527-34. 1998
    ..The aim of the present trial was to determine whether or not this dose is practically applicable to Japanese patients with relapsed B-cell lymphoma with respect to safety, pharmacokinetics and efficacy...
  90. pmc Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy
    T Watanabe
    Hematology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 103:1580-7. 2010
    ..A tractable system to evaluate combination drugs for use with bortezomib is essential to enable continuing clinical benefit from this drug...
  91. ncbi request reprint [New trends in the diagnosis and treatment of malignant lymphoma]
    Kensei Tobinai
    Hematology Division, National Cancer Center Hospital
    Nihon Igaku Hoshasen Gakkai Zasshi 63:81-8. 2003
    ..To further improve the therapeutic results, it is extremely important to conduct well-designed clinical trial consecutively...
  92. ncbi request reprint High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma
    T E Tanimoto
    Hematopoietic Stem Cell Transplant Unit, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Bone Marrow Transplant 32:131-7. 2003
    ..The high response rate with low relapse observed in this study suggests that RIST may be an effective alternative curative treatment for patients with advanced ML...
  93. ncbi request reprint Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation
    Y Kanda
    Stem Cell Transplant Unit, National Cancer Center Hospital, University of Tokyo, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
    Bone Marrow Transplant 28:689-92. 2001
    ..Resumption of acyclovir upon restarting immunosuppressive therapy might be important for the further prevention of VZV reactivation. The benefit of long-term low-dose acyclovir should be confirmed prospectively...
  94. ncbi request reprint Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan
    Y Kanda
    Stem Cell Transplant Unit, National Cancer Center Hospital, Tokyo, Japan
    Bone Marrow Transplant 27:437-44. 2001
    ..We concluded that antigenemia-guided pre-emptive therapy with a decreased dose of ganciclovir and response-oriented dose adjustment might be appropriate to decrease the toxicity of ganciclovir without increasing the risk of CMV disease...
  95. ncbi request reprint Clinicopathological features of pyothorax-associated lymphoma; a retrospective survey involving 98 patients
    H Narimatsu
    Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, and Department of Pathology, Toranomon Hospital, Tokyo, Japan
    Ann Oncol 18:122-8. 2007
    ..These findings prompt us to establish an optimal treatment strategy on the basis of risk stratification of individual patients...
  96. ncbi request reprint Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma
    Y Ogawa
    Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, and Hematology Division, National Cancer Center Hospital, Tokyo, Japan
    Ann Oncol 17:330-3. 2006
    ..The primary objective of this study was to investigate the tolerability, efficacy and pharmacokinetic profile of oral fludarabine phosphate in relapsed patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL)...
  97. ncbi request reprint Primary hepatic low-grade B-cell lymphoma of the mucosa-associated lymphoid tissue type: a case report and review of the literature
    Jun Murakami
    Hematology Division, National Cancer Center Hospital, Tokyo, Japan
    Int J Hematol 75:85-90. 2002
    ..The patient has been followed up for 1.5 years since surgical resection with no recurrence. The clinicopathologic characteristics and management of this rare disease are discussed...
  98. ncbi request reprint Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study
    Masahiro Tsuboi
    Department of Thoracic Surgery and Oncology, Tokyo Medical University and Hospital, 6 7 1 Nishi shinjuku, Shinjuku ku, Tokyo, Japan
    Jpn J Clin Oncol 39:163-8. 2009
    ..The efficacy and safety of weekly administration of epoetin beta (EPO) for chemotherapy-induced anemia (CIA) patients was evaluated...
  99. ncbi request reprint Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation
    Yoshinobu Kanda
    Stem Cell Transplant Unit, National Cancer Center Hospital, Tokyo, Japan
    Transplantation 73:568-72. 2002
    ..Preemptive therapy against cytomegalovirus (CMV) disease has succeeded in reducing the incidence of CMV disease, but the toxicity of ganciclovir remains problematic...
  100. ncbi request reprint Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan
    H Niiya
    Hematopoietic Stem Cell Transplant Unit, National Cancer Center Hospital, Tokyo, Japan
    Haematologica 86:1071-4. 2001
    ..Thus, the strategy for controlling immunosuppression after RIST should be modified according to the type of conditioning regimen applied...
  101. ncbi request reprint Primary cutaneous aspergillosis caused by Aspergillus ustus following reduced-intensity stem cell transplantation
    K Nakai
    Hematopoietic Stem Cell Transplant Unit, National Cancer Center Hospital, 1 1 Tsukiji 5 chome, Chuo Ku, Tokyo, 105 0045, Japan
    Ann Hematol 81:593-6. 2002
    ..Although this is an extremely rare complication after transplantation, this case highlights that we should pay more attention to primary cutaneous aspergillosis in severely immunosuppressed patients...